{"ModuleTitle": "Company Description", "CompanyName": "Alimera Sciences, Inc.", "Symbol": "ALIM", "Address": "6120 WINDWARD PARKWAY STE 290, ALPHARETTA, Georgia, 30005, United States of America", "Phone": "6789905740", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a\r\npharmaceutical company that specializes in the commercialization and development\r\nof prescription ophthalmic pharmaceuticals. Alimera was incorporated on June 4,\r\n2003 under the laws of the State of Delaware. We presently focus on diseases\r\naffecting the back of the eye, or retina, because we believe these diseases are\r\nnot well treated with current therapies and represent a significant market\r\nopportunity.\r\nILUVIEN\r\nOur only commercial product is ILUVIEN\u00ae, an intravitreal implant that treats\r\npatients by delivering a continuous microdose of the non-proprietary\r\ncorticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months.\r\n\"Intravitreal\" refers to the space inside the eye behind the lens that contains\r\nthe jelly-like substance called vitreous.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f02%2f0001267602-20-000029.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "J. Philip Jones", "title": "Chief Financial Officer"}, {"name": "Philip John Ashman", "title": "COO & SVP-Commercial Operations Europe"}, {"name": "Richard S. Eiswirth", "title": "President, Chief Executive Officer & Director"}, {"name": "Samer Kaba", "title": "Chief Scientific Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}